PURPOSEPayments from the drug industry influence physicians' prescribing decisions. Whether industry payments affect the likelihood that patients receive the guideline-preferred treatment for their ca...

Mount Sinai is the latest in a string of U.S. hospitals to reach similar agreements with the Trump administration.

The U.S. Food and Drug Administration derives most of its drug regulatory budget from "user fees" paid by pharmaceutical companies. This White Paper l

Subscription and open access journals from Sage, the world's leading independent academic publisher.

What California chooses in the next six months will determine whether a decade of Medicaid transformation holds or collapses and how the health and well-being of thousands or millions of California’s ...

This cross-sectional study evaluates the association between device industry payments to physicians and physician utilization of device-associated procedures across multiple specialties.

Negotiating drug prices at launch would ensure that patients and health programs get fair prices on prescription drugs at the outset, instead of first facing nearly a decade or longer of excessive pri...

Medicare-eligible beneficiaries have the option of receiving their benefits through traditional Medicare administered by the federal government or through private Medicare Advantage (MA) plans that re...

These payments can affect everything from prescribing patterns to pharma’s business strategy

This cohort study compares Medicare Advantage beneficiaries and traditional Medicare beneficiaries newly diagnosed with cancer with regards to timeliness of initial treatment, receiving the optimum in...

This case-control study estimates vaccine effectiveness of 2025-2026 COVID-19 vaccines among adults with COVID-19–associated emergency department or urgent care encounters and COVID-19–associated hosp...

Private equity (PE) involvement in the acquisition of health-care practices is rapidly expanding, with more than $750 billion invested over the past decade

This Viewpoint presents the history of the Health Resources & Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limit...

Cancer care in the United States is deeply influenced by the structure of private and public insurance programs, where benefit design, provider incentives, and administrative requirements shape both c...

Webex by Cisco is an AI-powered secure enterprise collaboration platform.

Hundreds of cases reported in the DRC after USAID has been dismantled and key scientific research canceled

This cohort study characterizes the prevalence of treatment for metastatic non–small cell lung cancer and predictors of its receipt over a time span ranging from when empiric cytotoxic regimens domina...

New paper, developed with input from diverse stakeholders, outlines policy options to strengthen the FDA pathway.

Tens of thousands of publications from 2025 might include invalid references generated by AI, a Nature analysis suggests.

When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked ...

“The volume of evidence behind a therapy has become inversely correlated with public trust in it,” writes Vikas Patel.

Key takeaways: Big Pharma is pushing to undermine Medicare drug price negotiation and let corporations price gouge for longer periods,…